Nanoencapsulation of antiviral nucleotide analogs

Journal of Drug Delivery Science and Technology

Volumn 19, Issue 6, 2009, Pages 385-390

  Hillaireau, H ^a,b   Couvreur, P ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b CNRS   (France)

Author keywords

Liposomes; Nanocapsules; Nanogels; Nanoparticles; Nucleotide analogs

Indexed keywords

ACRYLIC ACID DERIVATIVE; ADEFOVIR; CHOLESTEROL; CIDOFOVIR; DIDANOSINE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; MACROGOL; NUCLEOSIDE ANALOG; POLOXAMER; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ANTIVIRAL THERAPY; AQUEOUS SOLUTION; BIODEGRADABILITY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG STABILITY; DRUG STRUCTURE; HYDROPHILICITY; MACROPHAGE; NANOENCAPSULATION; PH; PHOSPHORYLATION; REVIEW;

EID: 74749099786     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(09)50081-0     Document Type: Review

References (43)

1. Van Rompay A.R., Johansson M., Karlsson A. - Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogs by human deoxyribonucleoside kinases and ribonucleoside kinases. - Pharmacol. Ther, 100, 119-139, 2003.
2. Balzarini J., Herdewijn P., De Clercq E. - Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′- dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent antihuman immunodeficiency virus compounds. - J. Biol. Chem, 264, 6127-6133, 1989.
3. Kukhanova M., Krayevsky A., Prusoff W., Cheng Y.C. - Design of anti-HIV compounds: from nucleoside to nucleoside 5′-triphosphate analogs. Problems and perspectives. - Curr. Pharm. Des, 6, 585-598, 2000.
4. Törnevik Y., Ullman B., Balzarini J., Wahren B., Eriksson S. - Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. - Biochem. Pharmacol, 49, 829-837, 1995.
5. De Clercq E. - Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections. - Expert Rev Anti Infect Ther, 1, 21-43, 2003.
6. Schäfer V., von Briesen H., Andreesen R., Steffan A., Royer C., Tröster S., Kreuter J., Rübsamen-Waigmann H. - Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting. - Pharm Res, 9, 541-546, 1992.
7. Bender A.R., von Briesen H., Kreuter J., Duncan I.B., Rübsamen-Waigmann H. - Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. - Antimicrob Agents Chemother, 40, 1467-71, 1996.
8. Löbenberg R., Araujo L., von Briesen H., Rodgers E., Kreuter J. - Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. - J Control Release, 50, 21-30, 1998.
9. Löbenberg R., Maas J., Kreuter J. - Improved body distribution of 14C-labelled AZT bound to nanoparticles in rats determined by radioluminography. - J Drug Target, 5, 171-9, 1998.
10. Dembri A., Montisci M.J., Gantier J.C., Chacun H., Ponchel G. - Targeting of 3′-azido 3′-deoxythymidine (AZT)-loaded poly(isohexylcyanoacrylate) nanospheres to the gastrointestinal mucosa and associated lymphoid tissues. - Pharm Res, 18, 467-73, 2001.
11. Couvreur P., Barratt G., Fattal E., Legrand P., Vauthier C. - Nanocapsule technology: a review. - Crit Rev Ther Drug Carrier Syst, 19, 99-134, 2002.
12. Lambert G., Fattal E., Pinto-Alphandary H., Gulik A., Couvreur P. - Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. - Pharm Res, 17, 707-14, 2000.
13. Lambert G., Bertrand J.R., Fattal E., Subra F., Pinto-Alphandary H., Malvy C., Auclair C., Couvreur P. - EWS fli-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice. - Biochem Biophys Res Commun, 279, 401-6, 2000.
14. Watnasirichaikul S., Davies N.M., Rades T., Tucker I.G. - Preparation of biodegradable insulin nanocapsules from biocompatible microemulsions. - Pharm Res, 17, 684-9, 2000.
15. Watnasirichaikul S., Rades T., Tucker I.G., Davies N.M. - Effects of formulation variables on characteristics of poly (ethylcyanoacrylate) nanocapsules prepared from w/o microemulsions. - Int J Pharm, 235, 237-46, 2002.
16. Hillaireau H., Le Doan T., Besnard M., Chacun H., Janin J., Couvreur P. - Encapsulation of antiviral nucleotide analogs azidothymidine-triphosphate and cidofovir in poly(iso-butylcyanoacrylate) nanocapsules. - Int J Pharm, 324, 37-42, 2006.
17. Pitaksuteepong T., Davies N.M., Tucker I.G., Rades T. - Factors influencing the entrapment of hydrophilic compounds in nanocapsules prepared by interfacial polymerisation of water-in-oil microemulsions. - Eur J Pharm Biopharm, 53, 335-42, 2002.
18. Guise V., Drouin J.Y., Benoit J., Mahuteau J., Dumont P., Couvreur P. - Vidarabine-loaded nanoparticles: a physicochemical study. - Pharm Res, 7, 736-41, 1990.
19. Simeonova M., Velichkova R., Ivanova G., Enchev V., Abrahams I. - Poly(butylcyanoacrylate) nanoparticles for topical delivery of 5-fluorouracil. - Int J Pharm, 263, 133-40, 2003.
20. Simeonova M., Velichkova R., Ivanova G., Enchev V., Abrahams I. - Study on the role of 5-fluorouracil in the polymerization of butylcyanoacrylate during the formation of nanoparticles. - J Drug Target, 12, 49-56, 2004.
21. Hillaireau H., Le Doan T., Chacun H., Janin J., Couvreur P. - Encapsulation of mono- and oligo-nucleotides into aqueous-core nanocapsules in presence of various water-soluble polymers. - Int J Pharm, 331, 148-52, 2007.
22. Hillaireau H., Le Doan T., Appel M., Couvreur P. - Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages. - J Control Release, 116, 346-52, 2006.
23. Couvreur P. Vauthier C. - Polyalkylcyanoacrylate nanoparticles as drug carrier: present state and perspectives. - J Control Release, 17, 187-198, 1991.
24. Neu M., Fischer D., Kissel T. - Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives. - J Gene Med, 7, 992-1009, 2005.
25. Rodriguez J.F., Rodriguez J.L., Santana J., Garcia H., Rosario O. - Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals. - Antimicrob Agents Chemother, 44, 3097-100, 2000.
26. Laham A., Claperon N., Durussel J.J., Fattal E., Delattre J., Puisieux F., Couvreur P., Rossignol P. - Liposomally-entrapped ATP: improved efficiency against experimental brain ischemia in the rat. - Life Sci, 40, 2011-6, 1987.
27. Korb V., Tep K., Escriou V., Richard C., Scherman D., Cynober L., Chaumeil J., Dumortier G. - Current data on ATP-containing liposomes and potential prospects to enhance cellular energy status for hepatic applications. - Crit Rev Ther Drug Carrier Syst, 25, 305-45, 2008.
28. Betageri G. - Liposomal encapsulation and stability of dideoxyinosine triphosphate. - Drug Dev Ind Pharm, 19, 531-539, 1993.
29. Betageri G. Burrell L. - Stability of antibody-bearing liposomes containing dideoxyinosine triphosphate. - Int J Pharm, 98, 149-155, 1993.
30. Betageri G.V., Jenkins S., Ravis W. - Drug delivery using antibody-liposome conjugates. - Drug Dev Ind Pharm, 19, 2109-2116, 1993.
31. Betageri G.V., Black C.D., Szebeni J., Wahl L.M., Weinstein J.N. - Fc-receptor-mediated targeting of antibody-bearing liposomes containing dideoxycytidine triphosphate to human monocyte/macrophages. - J Pharm Pharmacol, 45, 48-53, 1993.
32. Szebeni J., Wahl S.M., Betageri G.V., Wahl L.M., Gartner S., Popovic M., Parker R.J., Black C.D., Weinstein J.N. - Inhibition of HIV-1 in monocyte/macrophage cultures by 2′,3′-dideoxycytidine-5′- triphosphate, free and in liposomes. - AIDS Res Hum Retroviruses, 6, 691-702, 1990.
33. Oussoren C., Magnani M., Fraternale A., Casablanca A., Chiarantini L., Ingebrigsten R., Underberg W.J., Storm G. - Liposomes as carriers of the antiretroviral agent dideoxycytidine-5′-triphosphate. - Int J Pharm, 180, 261-70, 1999.
34. Dias A.S.P., Bester M.J., Britz R.F., Apostolides Z. - Animal models used for the evaluation of antiretroviral therapies. - Curr HIV Res, 4, 431-46, 2006.
35. Ropert C., Malvy C., Couvreur P. - Inhibition of the Friend retrovirus by antisense oligonucleotides encapsulated in liposomes: mechanism of action. - Pharm. Res, 10, 1427-1433, 1993.
36. Düzgünes N., Simões S., Slepushkin V., Pretzer E., Rossi J.J., De Clercq E., Antao V.P., Collins M.L., de Lima M.C. - Enhanced inhibition of HIV-1 replication in macrophages by antisense oligonucleotides, ribozymes and acyclic nucleoside phosphonate analogs delivered in pH-sensitive liposomes. - Nucleosides Nucleotides Nucleic Acids, 20, 515-523, 2001.
37. Düzgünes N., Simões S., Slepushkin V., Pretzer E., Flasher D., Salem I.I., Steffen G., Konopka K., Pedroso de Lima M.C. - Delivery of antiviral agents in liposomes. - Meth. Enzymol, 391, 351-373, 2005.
38. Vinogradov S., Batrakova E., Kabanov A. - Poly(ethylene glycol)-polyethyleneimine NanoGel (TM) particles: novel drug delivery systems for antisense oligonucleotides. - Colloids Surf B: Biointerfaces, 16, 291-304, 1999.
39. Vinogradov S.V., Bronich T.K., Kabanov A.V. - Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. - Adv Drug Deliv Rev, 54, 135-47, 2002.
40. Vinogradov S.V. - Polymeric nanogel formulations of nucleoside analogs. - Expert Opin Drug Deliv, 4, 5-17, 2007.
41. Vinogradov S.V. Kabanov A.V. - Synthesis of nanogel carriers for delivery of active phosphorylated nucleoside analogs. - Polymer Prepr, 228, 296, 2004.
42. Kohli E., Han H., Zeman A.D., Vinogradov S.V. - Formulations of biodegradable Nanogel carriers with 5′-triphosphates of nucleoside analogs that display a reduced cytotoxicity and enhanced drug activity. - J Control Release, 121, 19-27, 2007.
43. Vinogradov S.V., Kohli E., Zeman A.D. - Cross-linked polymeric nanogel formulations of 5′-triphosphates of nucleoside analogs: role of the cellular membrane in drug release. - Mol Pharm, 2, 449-61, 2005.